Merck & Co. is spending $9.2 billion for Cidara Therapeutics and its lead influenza antiviral that was dropped by Johnson & ...

After already halving its workforce twice since 2022, Sensei Therapeutics is forging ahead with another deep round of cuts. | After already halving its workforce twice since 2022, Sensei Therapeutics ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. | Neuro biotech Ovid Therapeutics' C-suite is metamorphosing, with co ...

Applied Therapeutics’ lack of progress on govorestat as well as the potential costs to come have led analysts to question ...

Bristol Myers Squibb and Johnson & Johnson have stopped a phase 3 anticoagulant trial early for futility, closing off one avenue to market for a molecule tipped to generate multibillion-dollar sales.

As part of that relocation, about 70 employees—less than 5% of the total at the site—are being laid off, the spokesperson said. Some affected staffers may be able to move to other positions within the ...

Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, ...

European life sciences investor Medicxi has raised 500 million euros (about $581.6 million) to go directly toward innovative ...

AbbVie is ending an eleven-year agreement with Alphabet’s Calico Labs, according to an internal email obtained by Stat News.

After dropping so-so early-stage results on its dual GLP-1/GLP-2 agonist earlier this year, fierce competition in the obesity ...

Mersana Therapeutics' decision earlier this year to go all-in on its antibody-drug conjugate Emi-Le appears to have paid ...

Bayer has cleared out four cancer candidates from its early-stage pipeline, including a STAT3 inhibitor acquired as part of ...